Zobrazeno 1 - 4
of 4
pro vyhledávání: '"J. Andrew Andrew Livingston"'
Autor:
Neeta Somaiah, J Andrew Andrew Livingston, Vinod Ravi, Heather Y. Lin, Behrang Amini, Luisa Maren Solis, Anthony Paul Conley, Maria Alejandra Zarzour, Joseph Aloysius Ludwig, Ravin Ratan, Wei-Lien Wang, Dejka M. Araujo, Shreyaskumar Patel, Christina Lynn Roland, Alexander J. Lazar, Richard Greg Gorlick, Edwin R. Parra, Cara L. Haymaker
Publikováno v:
Journal of Clinical Oncology. 40:TPS11594-TPS11594
TPS11594 Background: Anti-PD 1/PD-L1 blockade alone or in combination with anti-CTLA4 have yielded suboptimal results in most sarcoma subtypes. CD73, an ectonucleotidase, catalyzes the rate-limiting step for adenosine production in the extracellular
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6399cc1d14e3527a8324e56d9f7ed676
https://doi.org/10.1200/jco.2022.40.16_suppl.tps11594
https://doi.org/10.1200/jco.2022.40.16_suppl.tps11594
Autor:
Michael Nakazawa, J Andrew Andrew Livingston, Andrew Justin Bishop, Maria Alejandra Zarzour, Neeta Somaiah, Ravin Ratan, Jonathan Benjamin Gill, Elizabeth Urquiola, Kristi Posey, Beverly Ashleigh Guadagnolo, Richard Greg Gorlick, Robert S. Benjamin, Shreyaskumar Patel, Anthony Paul Conley
Publikováno v:
Journal of Clinical Oncology. 40:e23548-e23548
e23548 Background: Rhabdomyosarcomas are the most common soft tissue sarcoma in children, and the prognosis of pediatric ARMS has improved with the use of multi-modality therapies. However, ARMS in adults is rare, and long-term outcomes continue to b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ae204766af94b98670d7e5871981fd2a
https://doi.org/10.1200/jco.2022.40.16_suppl.e23548
https://doi.org/10.1200/jco.2022.40.16_suppl.e23548
Autor:
Prapassorn Thirasastr, Cissimol Joseph, Dejka M. Araujo, Robert S. Benjamin, Anthony Paul Conley, J Andrew Andrew Livingston, Joseph Aloysius Ludwig, Shreyaskumar Patel, Ravin Ratan, Vinod Ravi, Maria Alejandra Zarzour, Xiao Zhou, Neeta Somaiah
Publikováno v:
Journal of Clinical Oncology. 40:11542-11542
11542 Background: Ripretinib (R) is approved for 4th line treatment of GIST based on superior PFS and OS compared to placebo in a phase 3 study, with RR of 11.8% and PFS of 6.3 months (mo). In addition to having high potency against PDGFRA D842V, ava
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7ce285fbeee8c1b0b9f36fdb673b0b8a
https://doi.org/10.1200/jco.2022.40.16_suppl.11542
https://doi.org/10.1200/jco.2022.40.16_suppl.11542
Autor:
Maria Chang Swartz, Michael Roth, Goldy George, J. Andrew Andrew Livingston, Stephanie J. Wells, Clark Andersen, Jian Wang, Susan K. Peterson
Publikováno v:
Journal of Clinical Oncology. 39:280-280
280 Background: The COVID-19 pandemic has negatively impacted morbidity, mortality, and economic status globally. Adolescents and young adults (AYAs, age 15-39) with cancer may experience disparities in access to health care, compounded by social dis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::113615c87f6ee9f42b3579a67479a18c
https://doi.org/10.1200/jco.2020.39.28_suppl.280
https://doi.org/10.1200/jco.2020.39.28_suppl.280